SEARCH

SEARCH BY CITATION

The treatment of glioblastoma with nimustine and teniposide appeared to be as effective as temozolomide (TMZ) but was much less costly. The author of this report suggests initiating a new phase 3 trial comparing the 2 regimens to determine whether, despite its disproportionately higher cost, TMZ is justified further as standard for the treatment of this tumor entity.